View Older Stories View More Recent Stories
-
Roth Capital Downgrades Keurig Green Mountain (GMCR) to Neutral
-
Roth Trims PT, Ests on Canadian Solar (CSIQ); Execution in Canada, Japan Now Key
-
Hydrogenics Corp. (HYGS) Closes 1.5M Share Offering Priced at $15/sh
-
Roth Capital Keeps Stemline (STML) at 'Buy'; Still Plenty to See and Do in 2014
-
Roth Capital Starts Top Image Systems (TISA) at Buy
-
Sphere 3D to Acquire Overland Storage (OVRL) in All-Stock Deal
-
Roth Capital Starts Magellan Petroleum (MPET) at Buy
-
Roth Slashes PT on Plug Power (PLUG) to $3.75; Amid Positive Outlook, Several Areas Still Need Addressing
-
Roth Affirms Rexahn (RNN) at 'Buy'; Things Shaping Up for Solid Second-Half 2014
-
Roth Boosts PT on Coronado (CNDO) to $1.70; Sidelined Until TSO, CNDO-109 Trajectory Clears Up
-
Roth Capital Upgrades Summer Infant (SUMR) to Buy
-
Roth Keeps Cytori Therapeutics (CYTX) at 'Buy'; Still Encouraged by Streamlining Efforts
-
Roth Trims PT on Orion Energy Systems (OESX) to $6; LED Hiccup Doesn't Disrupt Story
-
Roth Capital Upgrades Neogenomics (NEO) to Buy
-
Roth Reiterates 'Sell' Rating, $1 PT on Dendreon (DNDN) Following Q1 Report; Totality of Risks Remain High
-
Roth Capital Downgrades Diamondback Energy (FANG) to Neutral
-
Roth Boosts Ests on JA Solar (JASO) Following Q1 Results
-
Curis' (CRIS) Q1 Results Flat; Erivedge Growth, Pipeline Remain in Focus - Roth
-
Keryx (KERX) Volatility Could Increase on Zerenex PDUFA Date Delay, but Risk Negligible - Roth
-
Notable Analyst Rating Changes 05/08: (SCTY) (YELP) (FOSL) Upgraded; (MRK) (AGN) (PENN) Downgraded
-
Roth Capital Downgrades PowerSecure (POWR) to Neutral
-
SolarCity (SCTY) Continues Making Demonstrated Material Progress; Roth Upgrades to 'Buy'
-
Roth Capital Upgrades SolarCity (SCTY) to Buy
-
Roth Affirms Ligand Pharma (LGND) at 'Buy'; Captisol, Promacta Lead Strong Q1 Results
-
Roth Keeps Galena (GALE) at 'Buy' Following Q1 Report; Still Bullish on Abstral Following Revenue Results
-
Roth Slashes PT on Dendreon (DNDN) to $1; Multiple Hurdles Still Exist
-
Residential Bookings, Retained Value/Watt Key for SolarCity (SCTY) into Q1 Report - Roth
-
Cytokinetics' (CYTK) Q1 Results Solid, BENEFIT Remains in Focus - Roth
-
Roth Capital Upgrades Hecla Mining (HL) to Buy
-
Roth Capital Upgrades Golden Minerals Company (AUMN) to Buy
-
Roth Positive on MEI Pharma (MEIP) Following ME-344 Phase 1b Initiation
-
Pharmacyclics (PCYC) Story Unchanged Following Q1 Report; Roth Reiterates at 'Buy'
-
Roth Capital Upgrades Maxwell Technologies (MXWL) to Buy
-
Celldex (CLDX) Upcoming Clinical Data, Study Expansions, Pipeline Keep Roth Positive; 'Focus List' Rating Affirmed
-
Roth Comments on Palatin's (PTN) BMT Agreement with European Partner; Reaffirms 'Buy' Rating
-
Viggle, Inc. (VGGL) Closes 4.38M Common Offering for Gross Proceeds of $35M
-
Roth Positive on Cytokinetics (CYTK) Following BENEFIT-ALS Update; Several Points Go in Tirasemtiv's Favor
-
Roth Affirms Ligand (LGND) at Buy; FDA Grants Promacta/Revolade Priority Review
-
Roth Capital Upgrades Trinity Biotech (TRIB) to Buy
-
New BENEFIT-ALS Data from Cytokinetics (CYTK) is 'Exciting'; Investors Should Regain Confidence - Roth
-
Roth Capital Downgrades Ultra Clean (UCTT) to Neutral
-
DoD Supporting Galena's (GALE) NeuVax Provides Important Third-Party Scientific Validation - Roth
-
Viggle, Inc. (VGGL) NASDAQ Uplisting/IPO Opens Lower
-
Roth Slashes PT on Cytokinetics (CYTK) to $13; ALS Call Missed, but Omecamtiv Provides Buffer
-
Viggle, Inc. (VGGL) Prices Larger 4.38M Common Offering at $8 Apiece
-
Zerenex Costs Savings, Differentiation Highlighted; PDUFA Date Still in Focus (KERX) - Roth Capital
-
Roth 'Encouraged' to See Bavituximab Moving Forward; Affirms Peregrine Pharma (PPHM) at 'Buy'
-
Roth Capital Pounds Table on Cytokinetics (CYTK) into AAN BENEFIT-ALS Presentation
-
Roth Capital Starts GSV Capital (GSVC) at Buy
-
Notable Analyst Rating Changes 04/21: (MS) (AWI) (HNI) Upgraded; (WLT) (MGI) (YUM) Downgraded

